3 Dec 2019 15:09
3 December 2019
Cello Health plc
("Cello" or the "Company")
Total Voting Rights
As at 2 December 2019, Cello's issued share capital comprises 106,683,196 ordinary shares of 10 pence each ("Ordinary Shares"), of which 453,000 Ordinary Shares are held in treasury. The total number of current voting rights in the Company is therefore 106,230,196 Ordinary Shares.
The above figure (106,230,196 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Cello Health plc | 020 7812 8460 |
Mark Scott, Chief Executive | |
Mark Bentley, Group Finance Director www.cellohealthplc.com | |
Cenkos Securities plc | 020 7397 8900 |
Giles Balleny | |
Harry Hargreaves | |
Buchanan Mark Court | 020 7466 5000 |
Jamie Hooper | |
Sophie Wills | |
|
About Cello Health plc
Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.
Cello Health plc enables clients to commercialise, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.
For further information, please visit: https://cellohealthplc.com
CLL.L (CLL)